AI-powered contentSome parts of this article are powered by AI.
Share this article
Gotrade News - Labcorp (LH) announced on Tuesday, November 17, 2026, a collaboration with Grupo Fleury to expand clinical trial operations in Brazil, according to Labcorp's official release. The company plans to launch local clinical trial kit assembly in early 2027, followed by laboratory operations expected by the end of 2027.
Regular-session close on November 17, 2026, New York time. Prices and changes: Yahoo Finance, cross-checked against the closing price on Nasdaq.com.
What Labcorp Announced
Through the collaboration, Labcorp plans to launch local clinical trial kit assembly operations in Brazil, followed by laboratory operations, to help sponsors conduct studies more efficiently while bringing services closer to research sites and patients across the country, the company said. Local kit assembly is expected to begin in early 2027, while laboratory operations remain in development and are expected to launch by the end of 2027. Both operations will use Labcorp's global systems, processes and quality standards to support multinational clinical trials. The release, issued at 4:30 p.m. ET, did not state a value for the collaboration.
Labcorp described Grupo Fleury as one of Brazil's leading healthcare and diagnostic groups, with extensive laboratory infrastructure, scientific expertise and a strong presence across the Brazil healthcare ecosystem. "Clinical trials today often span multiple countries, and sponsors need partners that can combine global expertise with local insight," said Brian Caveney, M.D., president, biopharma laboratory services and chief medical and scientific officer, Labcorp.
Why It Matters for LH
According to the release, Labcorp's wholly owned central laboratory network spans North America, Europe, Asia and Africa, and the collaboration in Brazil expands its clinical trial support capabilities across five continents. By establishing operations in Brazil, Labcorp said it expects to shorten kit delivery times, reduce reliance on international shipping and improve operational efficiency for clinical trial sponsors. The company described Brazil as a key destination for clinical research, supported by a diverse patient population and experienced investigators.
The company said its nearly 71,000 employees serve clients in approximately 100 countries. Labcorp also noted that its plans for Brazil are forward-looking statements and that actual results could differ materially from those the statements suggest.
What to watch next: Labcorp's quarterly dividend of $0.72 per share goes to stockholders of record as of the close of business on Tuesday, November 24, 2026, and is payable on Friday, December 11, 2026.
This article is for education and information only and is not investment advice. Investment decisions are yours to make after your own research.
This article was written with the help of AI and checked by the Gotrade team before publishing.
Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA). This content is for educational purposes only and does not constitute financial advice. Always do your own research (DYOR) before investing.
M. Alfathan Rahman is a content writer with over 3 years of experience developing digital content strategies across various industries, including fintech. He has experience producing content for tax-related websites and financial education platforms. His focus areas include data research, and crafting financial articles that are informative, accurate, and accessible to investors of all experience levels.